Rapid7, Inc. (RPD) Reaches $26.75 After 7.00% Down Move; Shorts at Vanda Pharmaceuticals (VNDA) Lowered By 0.78%

March 14, 2018 - By wolcottdaily

The stock of Rapid7, Inc. (NASDAQ:RPD) is a huge mover today! The stock decreased 2.80% or $0.77 during the last trading session, reaching $26.75. About 842,282 shares traded or 103.45% up from the average. Rapid7, Inc. (NASDAQ:RPD) has risen 56.77% since March 14, 2017 and is uptrending. It has outperformed by 40.07% the S&P500.The move comes after 7 months negative chart setup for the $1.20 billion company. It was reported on Mar, 14 by Barchart.com. We have $24.88 PT which if reached, will make NASDAQ:RPD worth $84.00M less.

Vanda Pharmaceuticals Inc (NASDAQ:VNDA) had a decrease of 0.78% in short interest. VNDA’s SI was 1.97M shares in March as released by FINRA. Its down 0.78% from 1.98 million shares previously. With 593,300 avg volume, 3 days are for Vanda Pharmaceuticals Inc (NASDAQ:VNDA)’s short sellers to cover VNDA’s short positions. The SI to Vanda Pharmaceuticals Inc’s float is 4.98%. The stock decreased 2.10% or $0.425 during the last trading session, reaching $19.775. About 173,489 shares traded. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 51.60% since March 14, 2017 and is uptrending. It has outperformed by 34.90% the S&P500.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company has market cap of $898.53 million. The companyÂ’s marketed products include HETLIOZ , a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. It currently has negative earnings. The Company’s clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

Investors sentiment decreased to 1.17 in 2017 Q3. Its down 0.26, from 1.43 in 2017Q2. It fall, as 12 investors sold Vanda Pharmaceuticals Inc. shares while 34 reduced holdings. 21 funds opened positions while 45 raised stakes. 38.89 million shares or 4.39% more from 37.25 million shares in 2017Q2 were reported. Sg Americas Secs Limited Co accumulated 8,828 shares. Panagora Asset Mngmt Incorporated reported 0.02% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). United Kingdom-based Barclays Public Ltd Company has invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Los Angeles Management Equity Research has invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Nationwide Fund reported 41,085 shares. First Mercantile Trust invested in 0.02% or 5,980 shares. Pnc Fincl Services Grp holds 0.01% or 348,350 shares in its portfolio. Morgan Stanley reported 1.08 million shares. Qs Investors Ltd Liability Company reported 0.05% stake. Boston Advsr Limited Co holds 15,515 shares or 0.01% of its portfolio. Tower Cap Limited Liability Com (Trc) invested 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Manufacturers Life Insurance The invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). The Minnesota-based Kopp Invest Advisors Llc has invested 0.2% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Int Gru Inc reported 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Columbus Circle Invsts holds 0.02% or 57,310 shares in its portfolio.

Since January 2, 2018, it had 0 insider purchases, and 8 insider sales for $4.89 million activity. $2.93 million worth of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) was sold by Polymeropoulos Mihael Hristos. Another trade for 3,660 shares valued at $68,473 was sold by Gulino Richard L.. Shares for $159,605 were sold by Birznieks Gunther on Wednesday, February 28. Kelly James Patrick had sold 8,532 shares worth $159,712 on Wednesday, February 28.

Among 8 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vanda Pharmaceuticals had 24 analyst reports since September 2, 2015 according to SRatingsIntel. The company was initiated on Wednesday, November 9 by Aegis Capital. The rating was initiated by Piper Jaffray on Tuesday, June 27 with “Buy”. The firm earned “Outperform” rating on Monday, October 30 by Oppenheimer. On Wednesday, February 28 the stock rating was maintained by Seaport Global with “Buy”. The rating was maintained by Piper Jaffray on Thursday, October 19 with “Buy”. The firm has “Buy” rating given on Tuesday, February 13 by Jefferies. The rating was initiated by Brean Capital on Wednesday, October 21 with “Buy”. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has “Buy” rating given on Monday, January 8 by Oppenheimer. Oppenheimer maintained Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) rating on Monday, March 5. Oppenheimer has “Buy” rating and $27.0 target. As per Wednesday, March 9, the company rating was maintained by JMP Securities.

Rapid7, Inc. provides security data and analytics solutions that enable organizations to implement an analytics-driven approach to cyber security and IT operations. The company has market cap of $1.20 billion. It offers threat exposure management solutions, including Nexpose, which enables clients to assess and remediate their exposure to cyber risk; Metasploit, a penetration testing software solution; and AppSpider, an application security testing solution. It currently has negative earnings. The firm also provides incident detection and response solutions, such as InsightIDR, a cloud based offering for incident detection and response; Managed Detection and Response, a managed service, which provides clients with attacker behavior analytics, machine learning algorithms, and threat intelligence to hunt attackers; and incident response services that provide clients with access to security experts and experience.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: